MAPT and Alzheimer disease: Furthermore, elevating miR-195 ameliorated cognitive deficits, amyloid plaque burden, and tau hyper-phosphorylation in ApoE4 (+/+) mice and rescued AD-related lysosomal defects in inducible pluripotent stem cells (iPSCs)-derived brain cells of ApoE4 (+/+) AD patients, while inhibiting miR-195 exacerbated these phenotypes by targeting synaptojanin 1 (synj1) (Cao et al., 2020).